What’s preventing #biosimilars from becoming the cost-saving solution they were meant to be? Despite high hopes, these alternatives to #biologics are struggling to make an impact. RxBenefits Chief Pharmacy Officer Mark Campbell, PharmD, explains the market dynamics holding back adoption and highlights the missed opportunity. Get the story now: https://rxbene.fit/3zCoz10 #RxBenefits #Pharmacybenefits
RxBenefits, Inc.’s Post
More Relevant Posts
-
Assistant Vice President - System Oncology, Infusion & Investigational Drug Pharmacy Services | 40 Under 40 in Cancer | Board Advisor | Professional Organization Executive
Headed to the 2024 ASHP Futures meeting to share new insights on all things biosimilars. Tell me what you would like addressed; tailoring the discussion to the audience's needs and opportunities is my favorite part of these programs. Join us, with questions! Follow our team at #MCIrxPineapplePride #ASHP24 #Biosimilars #Biologics
-
-
Looking for a convenient way to stay up-to-date on the latest breakthroughs in biologics and tides? Subscribe to our monthly newsletter so that you never miss another update. 📰✨ Sign up now! 👉https://hubs.la/Q02HcqzX0 #OGBiologics #Biologics
-
-
Jill Zouzoulas, M.D. discusses how they evaluate the costs between intravenous and subcutaneous therapies when deciding which route of administration to use in patients and the impact IV biosimilars have had on treatment decisions. Watch this K-Cast to find out more: https://bit.ly/3WGMRQ5. #ManagedCare #Biologics #Biosimilars
-
-
Managing Director @ Laboratoire CellMade, Procomcure France - Food Industry, Pharmaceutics
📢 Ensure product safety and comply with regulations using MAT, the reliable and ethical animal-free pyrogen detection test! 📢 Pyrogens in pharmaceuticals, biotherapeutics, and medical devices can cause serious health risks to patients. The Monocyte Activation Test (MAT) offers a cutting-edge solution for pyrogen detection, surpassing traditional methods in accuracy and ethical considerations. ✅ Human-relevant: Based on the human immune response for precise pyrogenic activity prediction. ✅ Broad spectrum: Detects both endotoxin and non-endotoxin pyrogens. ✅ Ethical: Eliminates animal testing, aligning with ethical standards. ✅ Reliable: Recognized by international health authorities and compliant with Ph. Eur. 2.6.30 and 2.6.40. The European Pharmacopoeia now recommends MAT as a replacement for the rabbit pyrogen test. Contact Procomcure France today to implement and validate MAT for your specific products. #pyrogentesting #MAT #animalfree #pharmaceuticals #biologics #medicaldevices #qualitycontrol #regulatorycompliance #ProcomcureFrance
-
📢 Ensure product safety and comply with regulations using MAT, the reliable and ethical animal-free pyrogen detection test! 📢 Pyrogens in pharmaceuticals, biotherapeutics, and medical devices can cause serious health risks to patients. The Monocyte Activation Test (MAT) offers a cutting-edge solution for pyrogen detection, surpassing traditional methods in accuracy and ethical considerations. ✅ Human-relevant: Based on the human immune response for precise pyrogenic activity prediction. ✅ Broad spectrum: Detects both endotoxin and non-endotoxin pyrogens. ✅ Ethical: Eliminates animal testing, aligning with ethical standards. ✅ Reliable: Recognized by international health authorities and compliant with Ph. Eur. 2.6.30 and 2.6.40. The European Pharmacopoeia now recommends MAT as a replacement for the rabbit pyrogen test. Contact Procomcure France today to implement and validate MAT for your specific products. #pyrogentesting #MAT #animalfree #pharmaceuticals #biologics #medicaldevices #qualitycontrol #regulatorycompliance #ProcomcureFrance
-
Navigating #biologics and #biosimilars is a challenge for #payers. Effective data management is key to creating holistic member records and optimizing formularies. With biosimilars offering up to 30% cost savings, the right tools can unlock huge ROI. This Expert Insight from Wolters Kluwer has all the details: https://gag.gl/XKNjZL #PayerSolutions #HealthcareInnovation #MediSpan
-
Account & Relationship Management Executive @ Wolters Kluwer Health | Clinical Effectiveness
Navigating #biologics and #biosimilars is a challenge for #payers. Effective data management is key to creating holistic member records and optimizing formularies. With biosimilars offering up to 30% cost savings, the right tools can unlock huge ROI. This Expert Insight from Wolters Kluwer has all the details: https://gag.gl/XKNjZL #PayerSolutions #HealthcareInnovation #MediSpan
Understanding biologics and biosimilars and their impact on health plan formularies
wolterskluwer.com
-
🙌 Promea Therapeutics thanks to all channel partners, vendors, and customers for your unwavering support as we close another successful financial year! 🚀 Your collaboration and trust have been instrumental in our journey towards excellence. Here's to continued success and growth together! 💼 #Promea #Diagnostics #Biologics #IVFluids #MakeInIndia #OurPromeaOurPride #PromeaGratitude #FinancialYearClosing #PartnershipSuccess #DiagnosticsExcellence 🎉
-
-
We are very pleased to announce that Ziccum has gone live at DI.se. Please find a dedicated company page tracking the company’s stock performance, access to reports, investor relations announcements, and a company profile, including a concise company overview video featuring Ziccum’s CEO, Ann Gidner, here: https://lnkd.in/dAuhYZJ5. #ziccum #laminarpace #disruptivetechnology #disruptive #innovation #biologics #mrna #rna #mrnalnp #lipidnanoparticles #biologics #dryingbiologics #vaccine #formulation #drugformulation #lnpformulation #thermostability #vaccinedelivery #inhalation #inhaledbiologics #particleengineering #carbonfootprint #vaccinedevelopment #drugdevelopment
-
-
SVP, Global External Affairs and Board Secretary @USP | Government Affairs, Public & Regulatory Policy, Communications, board executive in biopharma. Views are my own!
This is good news. Eliminating the ‘interchangeability’ hurdle will remove yet one more barrier to access and help unleash the savings that biosimilars offer. There is so much real world evidence that ‘interchangeability’ is merely a regulatory construct and not clinically meaningful. We only have to look at Europe’s experience for validation. It has far higher biosimilars adoption, more approved and marketed products, and many more years of experience with biosimilars. They don’t have a regulatory hurdle for ‘interchangeability’ and they have no evidence of any adverse clinical impacts on patients. What they do have is more patient access and far more cost savings than the US.
“The Biosimilars Council applauds the administration for including biosimilars in their proposed budget,” said Craig Burton, Executive Director, Biosimilars Council and AAM Senior Vice President, Policy and Strategic Alliances. “The distinction between interchangeable #biologics and #biosimilars is not supported by science and continues to permit brand misinformation. The proposal would reduce confusion and increase #patientaccess to lower cost biosimilars.”
Biosimilars Council Applauds the President's Budget Proposal to Eliminate the Arbitrary Distinction between Interchangeable Biologics and Biosimilars - Biosimilars Council
